


CLAIMS

1. A compound of formula (VIa):



wherein

het¹ represents a substituted or unsubstituted 9 membered bicyclic heteroaryl group comprising a 5 membered ring, wherein the 5 membered ring comprises 1 or 2 nitrogen atoms, and a 6 membered ring, wherein the 6 membered ring comprises 1 or 2 nitrogen atoms, and when substituted the ring system is substituted with 1, 2, or 3 groups independently selected at each occurrence from the group consisting of halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, -OR^{A2}, -NR^{A2}R^{B2}, -CN, -SO₂R^{A2}, and C₃₋₆ cycloalkyl;

het² is a 5 or 6 membered heterocyclic ring which may be unsubstituted or substituted, and when substituted the ring is substituted with 1, 2 or 3 groups independently selected at each occurrence from the group consisting of halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, -OR^{A1}, -NR^{A1}R^{B1}, -CN, -NO₂, -NR^{A1}C(O)R^{B1}, -C(O)NR^{A1}R^{B1}, -NR^{A1}SO₂R^{B1}, -SO₂NR^{A1}R^{B1}, -SO₂R^{A1}, -C(O)R^{A1}, -C(O)OR^{A1} and C₃₋₆ cycloalkyl;


R³ is selected from the group consisting of H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and C₃₋₆ cycloalkyl;











R⁴ is independently selected at each occurrence from the group consisting of halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, -CN, -OR^{A4}, -NR^{A4}R^{B4}, -SO₂R^{A4}, C₃₋₆ cycloalkyl and C₃₋₆ halocycloalkyl;







n is 0, 1 or 2; and







R^{A1}, R^{B1}, R^{A2}, R^{B2}, R^{A4} and R^{B4} are at each occurrence independently selected from the group consisting of H, C₁₋₄ alkyl, and C₁₋₄ haloalkyl.







2. The compound of claim 1, wherein het^2 represents a ring selected from the group consisting of unsubstituted or substituted: pyrazole, imidazole, pyridine, pyrazine, pyrimidine, pyridazine, pyran, tetrahydropyran, dihydropyran, piperidine, piperazine, morpholine, thiomorpholine, oxazine, dioxine, dioxane, thiazine, oxathiane and dithiane.
3. The compound of claim 1, wherein het^1 represents a group selected from the group consisting of unsubstituted or substituted: indolizine, purine, pyrrolopyrimidine, pyrazolopyrimidine, azaindole, and azaisoindole.
4. The compound of claim 1, wherein R^3 is H or methyl.
5. The compound of claim 1, wherein R^4 is independently selected at each occurrence from the group consisting of H, chloro, fluoro, methyl, ethyl, trifluoromethyl, trifluoroethyl, $-\text{OCF}_3$, $-\text{OH}$, $-\text{OMe}$, $-\text{OEt}$, $-\text{NH}_2$, $-\text{NHMe}$, and $-\text{NMe}_2$.
6. The compound of claim 1, wherein n is 0.
7. The compound of claim 1, wherein the compound is selected from the group consisting of:



















and



8. A compound of claim 1 for use in the treatment of a condition modulated by Wnt signalling or the inhibition of porcupine (Porcn), which is selected from the group consisting of, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia.
9. A compound of claim 1 for use in the treatment of a condition modulated by Wnt signalling or the inhibition of Porcn, which is selected from the group consisting of esophageal squamous cell carcinoma, gastric cancer, glioblastomas, astrocytomas, retinoblastoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, rhabdomyosarcoma, Wilm's tumor, basal cell carcinoma, non-small cell lung cancer, brain tumour, prostate cancer, breast cancer, pancreatic cancer, colorectal cancer, cervical cancer, and cancer of the head and neck.
10. A compound of claim 1 for use in the treatment of a condition modulated by Wnt signalling or the inhibition of Porcn, which is selected from the group consisting of skin fibrosis, idiopathic pulmonary fibrosis, renal interstitial fibrosis, liver fibrosis, proteinuria, kidney graft rejection, osteoarthritis, Parkinson's disease, cystoid macular edema, uveitis associated cystoid macular edema, and retinopathy.
11. A pharmaceutical formulation comprising a compound of claim 1; and a pharmaceutically acceptable excipient.
12. The pharmaceutical composition of claim 11, further comprising an additional pharmaceutically active agent.
13. A compound of formula (VIb):



wherein

het¹ represents a substituted or unsubstituted 9 membered bicyclic heteroaryl group comprising a 5 membered ring, wherein the 5 membered ring comprises 1 or 2 nitrogen atoms, and

a 6 membered ring, wherein the 6 membered ring comprises 1 or 2 nitrogen atoms, and when substituted the ring system is substituted with 1, 2, or 3 groups independently selected at each occurrence from the group consisting of halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, -OR^{A2}, -NR^{A2}R^{B2}, -CN, -SO₂R^{A2}, and C₃₋₆ cycloalkyl;

het² is a 5 or 6 membered heterocyclic ring which may be unsubstituted or substituted, and when substituted the ring is substituted with 1, 2 or 3 groups independently selected at each occurrence from the group consisting of halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, -OR^{A1}, -NR^{A1}R^{B1}, -CN, -NO₂, -NR^{A1}C(O)R^{B1}, -C(O)NR^{A1}R^{B1}, -NR^{A1}SO₂R^{B1}, -SO₂NR^{A1}R^{B1}, -SO₂R^{A1}, -C(O)R^{A1}, -C(O)OR^{A1} and C₃₋₆ cycloalkyl;

R³ is selected from the group consisting of H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and C₃₋₆ cycloalkyl;

R⁴ is independently selected at each occurrence from the group consisting of halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, -CN, -OR^{A4}, -NR^{A4}R^{B4}, -SO₂R^{A4}, C₃₋₆ cycloalkyl and C₃₋₆ halocycloalkyl;

n is 0, 1 or 2; and

R^{A1}, R^{B1}, R^{A2}, R^{B2}, R^{A4} and R^{B4} are at each occurrence independently selected from the group consisting of H, C₁₋₄ alkyl, and C₁₋₄ haloalkyl.


14. The compound of claim 13, wherein het² represents a ring selected from the group consisting of unsubstituted or substituted: pyrazole, imidazole, pyridine, pyrazine, pyrimidine, pyridazine, pyran, tetrahydropyran, dihydropyran, piperidine, piperazine, morpholine, thiomorpholine, oxazine, dioxine, dioxane, thiazine, oxathiane and dithiane.

15. The compound of claim 13, wherein het¹ represents a group selected from the group consisting of unsubstituted or substituted: indolizine, purine, pyrrolopyrimidine, pyrazolopyrimidine, azaindole, and azaisoindole.

16. The compound of claim 13, wherein R³ is H or methyl.

17. The compound of claim 13, wherein R⁴ is independently selected at each occurrence from the group consisting of H, chloro, fluoro, methyl, ethyl, trifluoromethyl, trifluoroethyl, -OCF₃, -OH, -OMe, -OEt, -NH₂, -NHMe, and -NMe₂.

18. The compound of claim 13, wherein n is 0.
19. The compound of claim 13, wherein the compound is selected from the group consisting of:



20. A compound of claim 13 for use in the treatment of a condition modulated by Wnt signalling or the inhibition of Porcn, which is selected from the group consisting of sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia.
21. A compound of claim 1 for use in the treatment of a condition modulated by Wnt signalling or the inhibition of porcupine (Porcn), which is cancer.
22. A compound of claim 13 for use in the treatment of a condition modulated by Wnt signalling or the inhibition of porcupine (Porcn), which is cancer.
23. A compound of claim 1 for use in the treatment of a condition modulated by Wnt signalling or the inhibition of Porcn, which is selected from the group consisting of hormone refractory

prostate cancer, metastatic breast cancer, metastatic pancreatic cancer, and head and neck squamous cell carcinoma.

24. A compound of claim 1 for use in the treatment of a condition modulated by Wnt signalling or the inhibition of Porcn, which is selected from diabetic retinopathy and retinopathy of prematurity.